What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?
The Motley Fool
JANUARY 14, 2024
That's nearly five times the amount of its total liabilities: $359 million. CRISPR could pay off all of its liabilities, both short and long term, and still have more than $1 billion left in short-term liquid assets. As of Sept. 30, the biotech had cash and marketable securities worth more than $1.7
Let's personalize your content